Document Detail

Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy.
MedLine Citation:
PMID:  25282317     Owner:  NLM     Status:  Publisher    
Guidelines now recommend high-intensity statin therapy in all patients with proven atherosclerotic disease. Yet the impact of baseline lipoprotein and C-reactive protein (CRP) levels on measures of disease regression to this therapy are unknown. The aim of this study was to test the hypothesis that high-intensity statin therapy causes equivalent degrees of coronary atheroma regression irrespective of baseline lipoprotein and CRP levels. In 8 prospective randomized trials using serial coronary intravascular ultrasound, 1,881 patients who maintained or switched to 18- to 24 months of high-intensity statin therapy (rosuvastatin 40 mg or atorvastatin 80 mg) were stratified according to baseline lipoprotein and CRP levels. Changes in coronary percentage atheroma volume (PAV) and total atheroma volume (TAV) were evaluated. High-intensity statin therapy produced significant reductions from baseline in low-density lipoprotein cholesterol by 38.4%, non-high-density lipoprotein (HDL) cholesterol by 33.6%, triglycerides by 13.1%, and CRP by 33.3%, while increasing HDL cholesterol by 11.7% (p <0.001 for all). This was associated with regression of PAV by 0.7% and of TAV by 8.2 mm(3) (p <0.001 for both). No significant differences of changes in PAV and TAV were observed across baseline quintiles of low-density lipoprotein cholesterol, HDL cholesterol, non-HDL cholesterol, triglycerides, or CRP. Moreover, across all measured lipoproteins and CRP, most patients demonstrated plaque regression (defined as any change from baseline in PAV or TAV <0). In conclusion, high-intensity statin therapy attenuated the natural progression of coronary atherosclerosis in all strata of patients with coronary artery disease irrespective of baseline lipoprotein or CRP levels. These findings provide support for the latest United States guideline recommendations for the broad use of high-intensity statin therapy in all patients with atherosclerosis, regardless of baseline lipid status.
Rishi Puri; Steven E Nissen; Mingyuan Shao; Kiyoko Uno; Yu Kataoka; Samir R Kapadia; E Murat Tuzcu; Stephen J Nicholls
Related Documents :
7713637 - Growth of hand-reared american kestrels. ii. body composition and wingloading of fledgl...
10670667 - Incidence of pecking damage in growing bantams in relation to food form, group size, st...
19474157 - Prebiotics modulate immune responses in the gut-associated lymphoid tissue of chickens.
11128387 - Intestinal digesta viscosity decreases during coccidial infection in broilers.
845617 - Suppression of acute and chronic experimental allergic encephalomyelitis in strain 13 g...
20562367 - Bacterial fermentation affects net mineral flux in the large intestine of pigs fed diet...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-27
Journal Detail:
Title:  The American journal of cardiology     Volume:  -     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-10-5     Completed Date:  -     Revised Date:  2014-10-6    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coronary Artery Calcium and Risk of Atrial Fibrillation (from the Multi-Ethnic Study of Atherosclero...
Next Document:  Utilization of predefined stimulation groups by essential tremor patients treated with VIM-DBS.